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"Once there is a union of sperm and egg, what you have is a living entity 
with a full and unique genetic character. There shouldn't be a moral 
coarsening of appreciation for life that allows us to think of it as nothing . .. ) 
Robert Royal 
"From the time that the ovum is fertilized, a new life is begun which is 
neither that of the father or the mother; it is rather the life of a new human 
being with his own growth. It would never be made human if it were not 
human already. To this perpetual evidence .... modern genetic science 
brings valuable confirmation. It has demonstrated that from the first 
instant, the program is fixed as to what this living being will be: a man, this 
individual man with his characteristic aspects already well determined. 
Right from fertilization is begun the adventure of a human life, and each of 
its great capacities requires time .... to find its place and to be in a position 
to act ... 2 
Congregationfor the Doctrine of the Faith 
Declaration on Procured Abortion, 12-13 
While still in office, President Clinton gave instructions to Dr. Harold 
Shapiro, Chair of the National Bioethics Advisory Committee (NBAC) to 
undertake a thorough review of the issues associated with human stem cell 
research. The dangerous conclusion of the NBAC was that ''this research is 
allied with a noble cause, and any taint that might attach from the source of 
stem cells diminishes in proportion to the potential good which the research 
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may yield.,,3 This is classic situation ethics where the ends justify the 
means. 
Researchers at the University of Wisconsin and Johns Hopkins 
University have successfully isolated and cultured human primordial stem 
cells. These stem cells have been shown to be building blocks for almost 
all human tissue. These pluripotent cells apparently have the capacity to 
differentiate into any of the human cell types. If their differentiation can be 
controlled, they could be used to grow healthy tissue that would augment or 
replace diseased tissues. Scientists believe this potential raises the 
possibility of growing spare body parts or correcting such disorders as 
diabetes, heart disease, cancer, and Parkinson' s disease. 
At the same time, we must consider how these stem cells are obtained. 
The isolation of stem cells involves the extraction and manipulation of cells 
harvested from the inner mass of blastocysts, a fluid-filled sphere made up 
of cells that will become the placenta, and 15-20 cells clinging together and 
to the inside of the blastocyst wall that will become the embryo. These 
inner cells will give rise to embryonic stem cells each identical to the 
others, and each able to become any kind of cell in the human body. These 
cell lines are derived from discarded or frozen embryos. Stem cells may be 
harvested from the gonadal tissue of aborted fetuses, rekindling the debate 
about the moral status of these entities and what we may ethically do with 
and to them. These studies raise questions about the interplay between 
private funding and public oversight of morally contested research. 
The Wisconsin group, led by James A. Thompson, published its work 
in the November 6, 1998 issue of Science. The "research and clinical 
potential for human embryonic stem cells is enormous," he writes. They 
will be used for studies of normal and abnormal human embryo 
development (birth defects), to test new drugs and especially "as a 
renewable source of cells for tissue transplantation, cell replacement and 
gene therapies.'.4 Thompson used blastocysts left over from in vitro 
fertilizations that would have been discarded. The donors of the 
blastocysts gave permission for them to be used in research. 
The Geron Corp. Ethics Advisory Board recently declared that human 
embryonic stem cell lines not originating with fetal tissue are obviously 
below the threshold for independent moral standing. The problem in 
applying EAB's "threshold" criterion of value is that no obvious threshold 
exists. The human being must be respected as a person from the very first 
instant of its existence. Respect for the dignity of the human being 
excludes all experimental manipulation or exploitation of the human 
embryo. The practice of keeping alive human embryos in vivo or in vitro 
for experimental or commercial purposes is totally opposed to human 
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dignity. It is immoral to produce human embryos destined to be exploited 
as disposable "biological materia\." 
The freezing of embryos, even when carried out in order to 
preserve the life of an embryo - cryopreservation - constitutes an 
offense against the respect due to human beings by exposing them 
to grave risks of death or harm to their physical integrity and 
denying them, at least temporarily, maternal shelter and gestation, 
thus placing them in a situation in which further offenses and 
manipulation are possible. S 
The excitement over the potential medical utility of embryonic stem 
cells obscures the important issues about the scientific use and commercial 
exploitation of human tissue. Geron Corp. financed research that derived 
stem cells from aborted fetuses and from donated human embryos left over 
from in vitro fertilization. The hypocrisy cries out when the Geron EAB 
concludes that it is wrong for couples to sell their embryos. The same 
arguments are used to argue that donors should not share in the profits 
resulting from research on their embryos. 
If it is wrong to commercialize embryos because of their nature, then 
it is wrong for everyone. It is simply inconsistent to argue that couples 
should act altruistically because commercializing embryos is wrong, while 
permitting corporations and scientists to profit financially from cells 
derived by destroying those embryos. 
The Geron EAB addresses the issue of global justice and the 
emerging world order, and the dangers of marketplace values, which often 
dominate the way power is deployed and human problems addressed. It 
fails miserably, though, in considering such issues as human dignity and 
inviolability, the value of the human embryo, and non-commodification of 
human life. It sets no concrete limit on the commercial exploitation of 
embryo and genetic research.6 In Europe, restrictions on cloning, embryo 
research and reproductive technologies apply to all relevant activities, 
whether privately or publicly funded. 
There are morally acceptable alternatives to the use of embryonic 
stem cells. New research involving adult stem cells and other advances in 
repair and regeneration of human tissue offer the promise that embryonic 
stem cells may simply be irrelevant to future medical progress. In the last 
two years there have been startling advances in isolating and culturing adult 
stem cells and even in the possibilities for dedifferentiating and 
redifferentiating them to produce a broader array of different cells and 
tissues.7 Advances in the use of growth factors to grow new blood vessels 
and nerve tissue and in the use of enzymes such as telomerase to 
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"immortalize" useful cell cultures also offer enormous promise, both in 
their own right and in combination with new knowledge about adult stem 
cells.8 
The issue of cell "immortal ity" is at the heart of this matter. The ends 
of chromosomes are sections of DNA called telomeres. They get a little 
shorter each time a cell divides until finally they hit a critical length that 
signals the cell to stop dividing. In January, 1998, Geron biologists 
reported that an enzyme called telomerase can keep the telomeres from 
shrinking, allowing cells to live and divide indefinitely (A characteristic 
which is also possessed by cancer cells.). Telomerase is active in 
embryonic stem cells, which as noted above can live and divide forever. 
When those cells start to differentiate into specific cells for specific organs, 
the telomorase disappears. The company is trying to find ways to make it 
reappear so it will work against the deterioration associated with aging. It 
is also looking for ways to block telomerase in treating cancer. An enzyme, 
tankyrase was isolated at Rockefeller University and scientists believe that 
it may control telomerase functioning. 
The moral problem of encouraging the destruction of human embryos 
for their stem cells is independent of any possible benefit expected from 
such research. Established by the Nuremberg Code, ethical norms on 
human experimentation have a demand that we never inflict death or 
disabling injury on any unconsenting individual of the human species 
simply for the sake of benefit to others. Stem cell research requiring the 
destruction and sacrifice of human embryos should not be supported by the 
government or supported by tax dollars. The existence of morally 
acceptable alternatives that do not involve the destruction of human life for 
research purposes would support the conclusion that support for embryo 
research is unethical, for it needlessly relies on the destruction of life to 
advance medical goals which can be achieved "in nondestructive ways. 
Contentious as the issue is, there are signs that public opinion may 
move toward support of at least limited embryo research. "Patients and 
their families faced with disabling diseases want science to move as 
quickly as possible," said Daniel Perry, executive of the Alliance for Aging 
Research.9 He heads a coalition of patient groups advocating research on 
embryonic stem cells. It must become clear to these organizations that 
while we have a moral obligation to the future health and welfare of 
people, we cannot and should not violate our motal obligation to the 
unborn . Human life is most vulnerable when it enters the world and when 
it leaves the realm of time to embark on eternity. Let us protect life 
throughout its miraculous development. 
"Before I formed you in the womb I knew you, and before you were 
born I consecrated you," (Jer. 1:5). 
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